top of page

PROGRAMME   EHMSG Workshop

Friday, September 8, 2023

08.00 – 10.00 hrs     Session 1:  What’s happening in H.pylori and gut microbiota

Chair: Annemieke Smet, Belgium, Christian Schulz, Germany

Room "Okapi"

08.00 – 08.20

01.01. Microbiome predicting the development of diseases in the population

Rinse Weersma, Groningen, The Netherlands

08.20 – 08.40

01.02. Helicobacter pylori: a stealth assassin

Richard Peek, Nashville, TN, USA
 

08.40 – 09.00

01.03. Breakthroughs and bottlenecks in microbiome research

Marie Joossens, Ghent, Belgium
 

09.00 – 09.20

01.04. Microbiota testing

Gianluca Ianiro, Rome, Italy
 

09.20 – 09.40

01.05. Impact of H. pylori eradication on gut microbiota

Jyhming Liou, Taipei, Taiwan
 

09.40 – 10.00

01.06. Gastric cancer and metabolomic profile

Jun-Young Seo, Seoul, Korea

10.00 - 10.30 hrs     Coffee Break

Room "Atrium" - Exhibition & Poster Area

10.30 – 12.30 hrs     Session 2: News on gastritis (Parallel Session)

Chair: Ari Ristimäki, Finland, Theodore Rokkas, Greece

Room "Okapi"

10.30 – 10.50

02.01. The evolution in gastritis classification - the REGAIN initiative

Massimo Rugge, Padua, Italy
 

10.50 – 11.10

02.02. H. pylori and its crosstalk to other gastric bacteria

Christian Schulz, Munich, Germany

11.10 – 11.30

02.03. The role of H. pylori and other microorganisms in autoimmune gastritis

Emanuele Dilaghi, Roma, Italy 

11.30 – 11.50

02.04. New developments and directions in protection against gastric disease and cancer

Thomas Boren, Umea, Sweden
 

11.50 – 12.02

02.05. GastroPanel, Ghrelin and Leptin for non-invasive diagnosis of advanced gastric atrophy and intestinal Metaplasia

Lukas Macke, Munich, Germany

12.02 – 12.14

02.06. Real-time gastric juice analysis for detection of Helicobacter pylori infection: is it useful in daily clinical practice?

André Trigo, Coimbra, Portugal

12.14 – 12.26

02.07. Gastric pathology and Helicobacter pylori vacA genotype in Indigenous communities of Arctic Canada

Taylor Cromarty, Edmonton, Canada

10.30 – 12.30 hrs     Session 3: Microbiome mechanisms of action (Parallel Session)

Chair: Mirjana Rajilić-Stojanović, Serbia, Lars Engstrand, Sweden

Room "Gorilla"

10.30 – 10.50

03.01. Oncobiome

Jorge Galena Nino, Seattle, WA, USA 

10.50 – 11.10

03.02. Using tools to make predictions

Tove Fall, Uppsala, Sweden
 

11.10 – 11.30

03.03. Microbial manipulation using model systems

Georgina Hold, Sydney, Australia
 

11.30 – 11.50

03.04. Dietary manipulation and its influence on microbial communities

Jeongseon Kim, Goyang-si, Korea

11.50 – 12.02                         

03.05. Mouth microbiome in children with autism: diagnosis-related differences and associations with behavioral difficulties

Margaux Evenepoel, Leuven, Belgium

 

12.02 – 12.14                         

03.06. KvarM lowers Klebsiella pneumoniae colonization in gastrointestinal tract without disruption of gut Microbiota

Indre Karaliute, Kaunas, Lithuania

 

12.14 – 12.26

03.07. Gut-vagina axis: Diet is associated with the vaginal microbiome

Isabell Erreygers, Antwerp, Belgium

12.30 – 14.00 hrs   Lunch Break & Poster Viewing

Room "Atrium" - Exhibition & Poster Area

14.00 - 16.00     Session 4: Helicobacter pylori Genome Project (HpGP) (Parallel Session)

Chair: Constanza Camargo, USA, Juozas Kupcinskas, Lithuania

Room "Gorilla"

14.00 – 14.10

04.01. Overview of HpGP
Constanza Camargo, Rockville, MD, USA

14.10 – 14.30

04.02. New insights into Helicobacter pylori population structure from the HpGP

Kaisa Thorell, Gothenburg, Sweden

14.30 – 14.50

04.03. Disclosing prophage genomics in the HpGP

Filipa Vale, Lisbon, Portugal

14.50 – 15.10

04.04. Identification and characterization of plasmids in Helicobacter pylori

Roberto Torres, Shanghai, China

15.10 – 15.30

04.05. The DNA methylases found in Helicobacter pylori strains

Rick Morgan, Ipswich, MA, USA

15.30 – 15.45

Q&A – participation of all HpGP investigators

15.45 – 16.00

04.06. Comprehensive analysis of Integrating Conjugative Elements (ICEs) in Helicobacter pylori populations

Wolfgang Fischer, Munich, Germany

14.00 - 16.00 hrs     Session 5: Microbiota modulation for a healthy life (Parallel Session)

Chair: Georgina Hold, Australia, Marie Joossens, Belgium

Room "Okapi"

14.00 – 14.20

05.01. Diet and lifestyle

Francesco Franceschi, Rome, Italy

14.20 – 14.40

05.02. Pre- and Probiotics

Mirjana Rajilić-Stojanović, Belgrade, Serbia

14.40 – 15.00

05.03. Postbiotics

Tom Van de Wiele, Ghent, Belgium

15.00 – 15.20

05.04. Antibiotics

Antonio Gasbarrini, Rome, Italy

15.20 – 15.32

05.05. Composition of infant gut virome associated with maternal antibacterial therapy and type of delivery

Egija Zelča, Riga, Latvia

15.32 – 15.44

05.06. Long-term outcomes of oral antibiotics combination therapy for induction and maintenance of ulcerative colitis

Toshifufi Ohkusa, Tokyo, Japan

15.44 – 15.56

05.07. Perceptions and practices on clinical use of probiotics: a national survey of healthcare practitioners.

Vasilios Papastergiou, Athens, Greece

 

16.00 - 16.30 hrs     Coffee Break

Room "Atrium" - Exhibition & Poster Area

16.30 - 18.30 hrs     Session 6: Gastric Carcinogenesis (Parallel Session)

Chair: José Machado, Portugal, Hwoon-Yong Jung, Korea

Room "Okapi"

16.30 – 16.50

06.01. A single H. pylori SNP controlling gastric cancer development

Steffen Backert, Erlangen, Germany

16.50 – 17.10

06.02. Cellular differentiation and neoplastic transformation of the gastric mucosa

Michael Sigal, Berlin, Germany

17.10 – 17.30

06.03. Gastric Cancer stem cells and metastasis

Christine Varon, Bordeaux, France

17.30 – 17.50

06.04. Impact of H. pylori infection on cancer immunotherapies

Dominique Velin, Lausanne, Switzerland

17.50 – 18.02                         

06.05. The humanized Leb mouse model with gastric cancer caused by life-long H. pylori infection

Artem Piddubnyi, Umea, Sweden

 

18.02 – 18.14                         

06.06. Study of Lactobacillus spp. effects on gastric carcinogenesis in the context of Helicobacter pylori Infection

Marine Jauvain, Bordeaux, France

 

18.14 – 18.26                         

06.07. Beneficial effect of sodium hydrosulfide, the hydrogen sulfide (H2S) donor on Helicobacter pylori (Hp)-infected fibroblasts in vitro. A key to therapeutic inhibition of Hp-carcinogenesis?

Tomasz Brzozowski, Cracow, Poland

16.30 - 18.30 hrs     Session 7: Microbiota modulation by FMT (Parallel Session)

Chair: Gianluca Ianiro, Italy, Josbert Keller, The Netherlands

Room "Gorilla"

16.30 – 16.50

07.01. FMT beyond Clostridioides difficile

Josbert Keller, Leiden, The Netherlands

16.50 – 17.10

07.02. FMT preparations: modification, lyophylization, or spores

Christian Hvas, Aarhus, Denmark

17.10 – 17.20

07.03. Safety of FMT and prospective registries

Maria Vehreschild, Frankfurt, Germany

17.20 – 17.35

07.04. Gastric microbiome modulation via FMT and immunity

Juan Du, Solna, Sweden

17.35 – 17.50

07.05. Factors underlying FMT efficacy

Harry Sokol, Paris, France

17.50 – 18.02

07.06. Double-blinded randomized controlled trial assessing the effect of triple faecal microbiota transplantation on hepatic steatosis in patients with non-alcoholic fatty liver disease

Bas Groenewegen, Leiden, The Netherlands

 

18.02 – 18.14                         

07.07. Comparative Efficacy of Encapsulated Fecal Microbiota Transplantation (FMT) and FMT via rectal enema for Irritable Bowel Syndrome (IBS): A Double-blind, Randomized, Placebo-controlled study (CAP-ENEMA FMT Trial)

Ratha-korn Vilaichone, Pathumthani, Thailand

                                                 

18.14 – 18.26                         

07.08. Mycobial community in monozygotic and dizygotic twins

Konrad Lehr, Magdeburg, Germany

 

 

20.00 hrs                Networking Dinner

Saturday, September 9, 2023

08.30 – 09.00 hrs     Session 8: Memorial Talks

Chair: Annemieke Smet

Room "Okapi"

08.30 – 08.45

08.01. In Memoriam Michel Deltenre

Ruffin Ntounda, Brussels, Belgium

                                                 

08.45 – 09.00

08.02. In Memoriam Jose Pajares

Javier Gisbert, Madrid, Spain

09.00 - 11.00 hrs     Session 9: H pylori management (Parallel Session)

Chair:  Javier Gisbert, Spain, Colm O’Morain, Ireland

Room "Okapi"

09.00 – 09.20

09.01. The search for new drug targets and therapies

Sinead Smith, Dublin, Ireland

09.20 – 09.40

09.02. Lessons from the first 10 years from the European registry

Olga Nyssen, Madrid, Spain 

09.40 – 10.00

09.03. Integration of antimicrobial susceptibility testing

David Graham, Houston, TX, USA

10.00 – 10.20

09.04. Personalised eradication treatment in Korea

Seong Woo Jeon, Daegu, Korea

10.20 – 10.32

09.05. Use of machine learning models to predict failure of Helicobacter pylori eradication therapy: A two country validation study

Wai Leung, Hong Kong

 

10.32 – 10.44

09.06. Susceptibility guided treatment of Helicobacter pylori infection: Serbian study experience

Vladimir Milivojevic, Belgrade, Serbia

 

10.44 – 10.56

09.07. Rifabutin-containing triple therapy versus bismuth quadruple therapy for Helicobacter pylori rescue treatment: a Multicenter, randomized controlled trial

Hong Lu, Shanghai, China

 

09.00 - 11.00 hrs     Session 10: Diseases & Microbiota (Parallel Session)

Chair: Francesco Franceschi, Italy, Jae Gyu Kim, Korea

Room "Gorilla"

09.00 – 09.20

10.01. Gastric cancer and microbiota

Emilie Bessède, Bordeaux, France

09.20 – 09.45

10.02. Mycobiota in cancer

Alexander Link, Magdeburg, Germany

09.45 - 10.10

10.03. Leaky gut and circulating microbiome

Juozas Kupcinskas, Kaunas, Lithuania

10.10. - 10.26                          

10.05. CagA determines the microbiome changes and risk of colorectal cancer elicited by Helicobacter pylori infection

Veronika Engelsberger, Munich, Germany

 

10.26 - 10.42                          

10.06. Lactobacillus - a new key player in gastric carcinogenesis?

Karla Vinasco, Kensington, Australia

 

10.42 - 10.58                          

10.07. Urinary lithogenic profile and gut and urinary microbiota in patients with inflammatory bowel disease

Irene Mignini, Rome, Italy

11.00 - 11.30 hrs     Coffee Break

Room "Atrium" - Exhibition & Poster Area

11.30 – 12.30 hrs   Session 11 - Industry Sponsored Satellite Symposium

Chair: Colm O'Morain, Ireland

Room "Okapi"

Please click HERE to view the detailed programme

12.30 – 14.30 hrs   Lunch Break & Poster Viewing

Room "Atrium" - Exhibition & Poster Area

14.30 - 15.30 hrs     Session 12: Debates – Search for the truth

Chair: Yaron Niv, Israel, Jan Tack, Belgium

Room "Okapi"

14.30 – 14.50

H.pylori is a protective factor for oesophageal disease

14.30 – 14.40    12.01. Yes: Theodore Rokkas, Athens, Greece

14.40 – 14.50    12.02. No: Jan Bornschein, Oxford, United Kingdom

14.50 – 15.10

Acid suppression can cause gastric cancer

14.50 – 15.00    12.03. Yes: Chan Hyuk Park, Seoul, Korea

15.00 – 15.10    12.04. No: Peter Malfertheiner, Munich, Germany

15.10 – 15.30

Microbiota in IBS: Chicken or egg?

15.10 – 15.20    12.05. Sébastien Kindt, Brussels, Belgium

15.20 – 15.30    12.06. Heiko de Schepper, Antwerp, Belgium

15.30 - 17.20 hrs     Session 13: Updates in Helicobacter & Microbiota

Chair: Marcis Leja, Latvia, Peter Malfertheiner, Germany

Room "Okapi"

15.30 – 15.50

13.01. Carcinogenesis and Lymphomagenesis - basic aspects

Mario D’Elios, Siena, Italy

15.50 – 16.10

13.02. Carcinogenesis and Lymphomagenesis - clinical aspects

Tamara Matysiak, Nantes, France

16.10 – 16.30

13.03. Gut microbiota and functional bowel disease

Jan Tack, Leuven, Belgium

16.30 – 16.50

13.04. Microbiota in reproductive health

Sarah Lebeer, Antwerp, Belgium

16.50 – 17.20

Clinical applications of gut microbiota (Tandem Talk)

16.50 – 17.05    13.05. Francis Chan, Hong Kong, China

17.05 – 17.20    13.06. Siew Ng, Hong Kong, China

17.20 - 18.30 hrs     Session 14: Closing Session

Chair: Annemieke Smet, Belgium & Francis Mégraud, France, José Machado, Portugal

Room "Okapi"

17.20 – 17.35                         

14.01. Genome and methylome variation in Helicobacter pylori infection - Relevance for Disease, Antibiotic Resistance and Vaccine Development

Sebastian Suerbaum, Munich, Germany

17.35 – 17.50

14.02.  A world without H. pylori

Barry Marshall, Australia

17.50 – 18.00                         
14.03. Awarding of the Marshall and Warren Medal 2023 to Youri Glupczynski, Brussels, Belgium

Francis Mégraud, France & Barry Marshall, Australia

18.00 – 18.10                         

14.04. Presentation of the Journal & Awarding of the best paper

Francesco Franceschi, Rome, Italy

18.10 – 18.20                         

14.05. Awarding of the EHMSG Oral and Poster Awards

18.20 – 18.30                         

14.06. Presentation of the next meeting in Porto, Portugal

José Machado, Porto, Portugal

Closing Remarks

bottom of page